Intravitreal Bevacizumab (Avastin®) in the Treatment of Neovascular Glaucoma
Accepted 23 June 2006. published online 02 August 2006.
Purpose
To describe a case series of neovascular glaucoma (NVG) caused by central retinal vein occlusion (CRVO) that was treated with intravitreal bevacizumab (IVB; Avastin®).
Design
Retrospective interventional case series.
Methods
Six consecutive patients with NVG and a refractory, symptomatic elevation of intraocular pressure (IOP) and pronounced anterior segment congestion received IVB (1.25 mg/0.05 ml). Diode laser cyclophotocoagulation was carried out only if pressure was controlled insufficiently by topical medication. Follow-up examinations occurred at four to 16 weeks.
Results
IVB resulted in a marked regression of anterior segment neovascularization and relief of symptoms within 48 hours. IOP decreased substantially in three eyes; in the other three eyes, adjuvant cyclophotocoagulation was necessary. No side effects were observed. Panretinal photocoagulation (PRP) was performed as soon as feasible, five to 12 weeks after IVB treatment.
Conclusion
IVB leads to a rapid regression of iris and angle neovascularization and should be investigated more thoroughly as an adjunct in the management of NVG.
Department of Ophthalmology, University of Bern, Inselspital, Bern, Switzerland
Inquiries to Milko E. Iliev, MD, Department of Ophthalmology, University of Bern, Inselspital, 3010 Bern, Switzerland
ABSTRACT